Evoke Pharma, Inc. (EVOK)
Total Valuation
Evoke Pharma has a market cap or net worth of $4.65 million. The enterprise value is $2.69 million.
| Market Cap | 4.65M |
| Enterprise Value | 2.69M |
Important Dates
The next estimated earnings date is Wednesday, November 8, 2023, after market close.
| Earnings Date | Nov 8, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 3.34 million shares outstanding. The number of shares has increased by 5.90% in one year.
| Shares Outstanding | 3.34M |
| Shares Change (YoY) | +5.90% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.46% |
| Owned by Institutions (%) | 2.07% |
| Float | 3.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| Forward PS | 1.70 |
| PB Ratio | 8.63 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 9.39.
| Current Ratio | 4.29 |
| Quick Ratio | 3.86 |
| Debt / Equity | 9.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.86 |
Financial Efficiency
Return on equity (ROE) is -258.20% and return on invested capital (ROIC) is -148.50%.
| Return on Equity (ROE) | -258.20% |
| Return on Assets (ROA) | -71.60% |
| Return on Capital (ROIC) | -148.50% |
| Revenue Per Employee | $892,562 |
| Profits Per Employee | -$1.98M |
| Employee Count | 4 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.46% in the last 52 weeks. The beta is 0.36, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.36 |
| 52-Week Price Change | -26.46% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 2.15 |
| Relative Strength Index (RSI) | 66.18 |
| Average Volume (30 Days) | 14,493 |
Short Selling Information
The latest short interest is 17,726, so 0.53% of the outstanding shares have been sold short.
| Short Interest | 17,726 |
| Short Previous Month | 3,643 |
| Short % of Shares Out | 0.53% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $3.57 million and -$7.93 million in losses. Loss per share was -$2.36.
| Revenue | 3.57M |
| Gross Profit | 3.18M |
| Operating Income | -7.56M |
| Pretax Income | -7.93M |
| Net Income | -7.93M |
| EBITDA | -7.31M |
| EBIT | -7.43M |
| Loss Per Share | -$2.36 |
Balance Sheet
The company has $7.01 million in cash and $5.05 million in debt, giving a net cash position of $1.95 million or $0.58 per share.
| Cash & Cash Equivalents | 7.01M |
| Total Debt | 5.05M |
| Net Cash | 1.95M |
| Net Cash Per Share | $0.58 |
| Equity / Book Value | 538,374 |
| Book Value Per Share | 0.16 |
| Working Capital | 6.85M |
Cash Flow
| Operating Cash Flow | -6.44M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.44M |
| FCF Per Share | -$1.93 |
Margins
Gross margin is 89.14%, with operating and profit margins of -211.80% and -222.06%.
| Gross Margin | 89.14% |
| Operating Margin | -211.80% |
| Pretax Margin | -222.06% |
| Profit Margin | -222.06% |
| EBITDA Margin | -204.88% |
| EBIT Margin | -208.05% |
| FCF Margin | -180.51% |
Dividends & Yields
Evoke Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -170.61% |
| FCF Yield | -138.69% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.90% |
| Shareholder Yield | -5.90% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 23, 2022. It was a reverse split with a ratio of 1:12.
| Last Split Date | May 23, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:12 |